KYORIN Pharmaceutical (4569) · RiskDropped
Intensifying Competition in Skincare Products
First written in FY2017-Q1. 3 of 5 entries say "Restated". Latest entry: FY2018.
5entries
3years
0from disclosures
How it moved
Same theme, other companies
Intensifying competition and price declines in the healthcare industryA theme 12 companies write about · 12 as a headwind · 0 as a tailwind
1 other company's latest entry also says "Dropped".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2018DroppedAnnual report
「Meanwhile, because all shares of Doctor Program Co., Ltd. were transferred to Taisho Pharmaceutical Co., Ltd. effective 1 April 2017, sales of skincare products declined.」
The previously cited risk of intensifying competition among skincare products is not repeated in this filing; instead, the decline in sales is explained as resulting from the business transfer. - FY2017RestatedAnnual report
「Although sales of skincare products fell below the previous year,」
It continues to describe sluggish sales of skincare products. - FY2017-Q3RestatedAnnual report
「Sales of skincare products fell below the previous year」
It continues to describe sluggish sales of skincare products. - FY2017-Q2RestatedAnnual report
「Amid uncertainty over an economic recovery, competition among skincare products intensified, and sales fell below the previous year.」
It continues to describe intensifying competition among skincare products and sales falling below the previous year. - FY2017-Q1First statedAnnual report
「Amid uncertainty over an economic recovery, competition among companies in skincare products intensified, and sales fell below the prior-year level.」
Intensifying competition and lower year-on-year sales are reported for skincare products.